Results 211 to 220 of about 435,208 (390)

Measurement and Estimation of Glomerular Filtration Rate in Children.

Advances in Chronic Kidney Disease, 2017
Ayesa N. Mian, G. Schwartz
semanticscholar   +1 more source

Incidence and Predictors of Hypoattenuated Thickening and Device‐Related Thrombus at Three Months Postprocedural CT Assessment Following Left Atrial Appendage Occlusion With Amplatzer Devices—A Single‐Center Cohort

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Left atrial appendage occlusion (LAAO) has become a valuable alternative to long‐term anticoagulation for stroke prevention in patients with non‐valvular atrial fibrillation (AF), especially in those at high bleeding risk. Hypoattenuated thickening (HAT) and device‐related thrombus (DRT) remain notable postprocedural concerns ...
Pierre Guilleminot, Carole Richard, Antoine Roger, Marlène Daller, Gabriel Laurent, Catherine Vergely, Charles Guenancia, Thibaut Pommier   +7 more
wiley   +1 more source

Accuracy of glomerular filtration rate estimates among patients with cancer. [PDF]

Br J Cancer
Lees JS, Fu EL, Faucon AL, Elyan BM, Inker LA, Levey AS, Jones RJ, Wilson RH, Mark PB, Carrero JJ.   +9 more
europepmc   +1 more source

Comparative Effect of African Walnut Oil and Docosahexaenoic Acid on, Cancer Antigen C15‐3, Biochemical and Histopathological Markers of Female Wistar Rats With 7,12‐Dimethylbenz[a]anthracene‐Induced Breast Cancer

Cancer Nexus, EarlyView.
ABSTRACT This work compares the effect of African walnut oil and docosahexaenoic acid (DHA) on cancer antigen C15‐3 (CA15‐3), biochemical, and histopathological markers of rats with 7,12‐dimethylbenz[a]anthracene‐induced (DMBA) breast cancer. 18 rats with tumor were randomized into three groups of six rats each: The negative control, the positive ...
Fabrice Tonfack Djikeng, Brenda Sandrine Tiadjo, Eurydice Flore Tiepma Ngongang, Hilaire Macaire Womeni   +3 more
wiley   +1 more source

Association of Intraindividual Difference in Cystatin C and Creatinine Estimated Glomerular Filtration Rate With Diabetes. [PDF]

J Diabetes Res
Zhang L, Yu Y, Zhao Y, Wang X.
europepmc   +1 more source

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First‐in‐Human Randomized, Double‐Blind, Placebo‐Controlled Single Ascending Dose Escalation Phase 1 Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective 5‐hydroxytryptamine 2C (5‐HT2C) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double‐blind, placebo‐controlled, single ascending dose (SAD) Phase 1 study aimed to assess the safety, tolerability, and pharmacokinetic (PK) and ...
Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R Srinivas, Randall Kaye   +6 more
wiley   +1 more source

Assessment of Glomerular Filtration Rate in Health and Disease: A State of the Art Review

Clinical pharmacology and therapy, 2017
A. Levey, LA Inker
semanticscholar   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT2C) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double‐blind, placebo‐controlled multiple ascending dose (MAD) study assessed the safety, tolerability, and ...
Jonathan Williams, Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R. Srinivas, Randall Kaye   +7 more
wiley   +1 more source

Combined Influence of Depressive Symptoms and Estimated Glomerular Filtration Rate on Cognition Decline in US Adults. [PDF]

Brain Behav
Yang Y, Hu H, Lv T, Li J, Yang Y, Chen S, He Y, Fei Q.   +7 more
europepmc   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source